

EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)

P. Gontero (Chair), E. Compérat, J.L. Dominguez Escrig,
F. Liedberg, P. Mariappan, A. Masson-Lecomte, A.H. Mostafid,
B.W.G. van Rhijn, M. Rouprêt, T. Seisen,
S.F. Shariat, E.N. Xylinas

Patient Advocates: I. Gürses Andersson, R. Wood

Guidelines Associates: O. Capoun, B. Pradere,
B.P. Rai, F. Soria, V. Soukup

Guidelines Office: C. Bezuidenhout

difference of 13–14% in the proportion of patients with recurrence. Contrary to these findings, two meta-analyses have demonstrated that BCG therapy may also reduce the risk of tumour progression [280, 281] (see Section 7.2.2.1) (LE: 1a). Moreover, BCG maintenance therapy appears to be significantly better in preventing recurrences than chemotherapy [282-284] (see Section 7.2.2.1) (LE: 1a). However, BCG causes significantly more side effects than chemotherapy [284] (LE: 1a).

Single instillation + further repeat instillations vs. later repeat instillations only

There is evidence from several studies in intermediate-risk patients that SI might have an impact on recurrence even when further adjuvant instillations are given [285-288]. A RCT including 2,243 NMIBC patients, which compared SI of MMC with an instillation of MMC delayed two weeks after TURB (followed by further repeat instillations in both treatment arms), showed a significant reduction of 9% in the risk of recurrence at 3 years in favour of SI, from 36% to 27%. The effect was significant in the intermediate- and high-risk groups of patients receiving additional adjuvant MMC instillations [285] (LE: 2a). Since the author's definition of the risk groups differed significantly in the initial publication, they adapted their patient stratification in the second analysis and consistently showed improved efficacy of SI followed by repeat MMC instillations [289]. The results of this study should be considered with caution since some patients did not receive adequate therapy. Another RCT found no impact of SI with epirubicin followed by further chemotherapy or BCG instillations in a cohort of predominant HR BC patients [290].

The optimal schedule of intravesical chemotherapy instillations

The length and frequency of repeat chemotherapy instillations is still controversial; however, it should not exceed one year [288] (LE: 3).

7.4.2.3 Options for improving efficacy of intravesical chemotherapy

7.4.2.3.1 Adjustment of pH, duration of instillation, and drug concentration

Two prospective RCTs showed that optimized intravesical administration of MMC reduced recurrence rates, either by a combination of measures (higher MMC-dose, peroral sodium bicarbonate, and refraining from drinking) [291] and by adding cytosine arabinoside [292], respectively (LE: 1b). The value of these measures in addition to alternative maintenance schedules is not known. Another trial reported that duration of a one-hour instillation of MMC was more effective compared to a 30-minute instillation, but no efficacy comparisons are available for one- vs. two-hour durations of instillation [293] (LE: 3). Another RCT using epirubicin has documented that concentration is more important than treatment duration [294] (LE: 1b). In view of these data, instructions are provided (see Section 7.7).

7.4.2.3.2 Device-assisted intravesical chemotherapy

Hyperthermic intravesical chemotherapy

Different technologies which increase the temperature of instilled MMC are available. A recent systematic review and meta-analysis including 4 RCTs suggests similar toxicity as for BCG with maintenance schedule [295].

Microwave-induced hyperthermia effect (RITE)

Promising data have been presented on enhancing the efficacy of MMC using microwave-induced hyperthermia in patients with high-risk tumours [296]. In one RCT comparing one year of BCG with one year MMC and microwave-induced hyperthermia in patients with intermediate- and high-risk BC, increased RFS at 24 months in the MMC group was demonstrated [297] (LE: 1b).

Conductive chemohyperthermia

In an open-label phase II RCT including 259 patients, HIVEC chemo-hyperthermia failed to demonstrate an improvement in DFS at 24 months over standard adjuvant intravesical chemotherapy in intermediate-risk NMIBC (61% vs. 60%), with a higher risk of treatment discontinuation (59% vs. 89% of completed planned treatments) [298].

In a pilot phase II RCT on 50 high-risk NMIBCs, HIVEC™ MMC showed early outcomes comparable to BCG (24 months RFS, 86.5% with HIVEC™ and 71.8% with BCG, $p = 0.184$) [299]. These data needs to be corroborated by further studies.

Electromotive drug administration

The efficacy of MMC using electromotive drug administration (EMDA) sequentially combined with BCG in patients with high-risk tumours has been demonstrated in one small RCT [300]. The definitive conclusion, however, needs further confirmation. For application of device-assisted instillations in patients recurring after BCG treatment, see Section 7.9.3.

decrease in efficacy with no decrease in toxicity [342] (LE: 1b). The EORTC did not find any difference in toxicity between one-third and full-dose BCG, but one-third dose BCG was associated with a higher recurrence rate, especially when it was given only for one year [318, 339] (LE: 1b). In a recent meta-analysis of 9 RCTs, patients who received less than half of the standard BCG dose experienced less adverse events as compared to patients receiving the full dose, but suffered more recurrences [343].

7.4.3.6 BCG shortage

A statement by the Panel on BCG shortage can be accessed online:

<https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/publications-appendices>.

7.4.3.7 Summary of evidence - BCG treatment

Summary of evidence	LE
In patients with intermediate- and high-risk tumours, intravesical BCG after TURB reduces the risk of tumour recurrence; it is more effective than TURB alone or TURB and intravesical chemotherapy.	1a
For optimal efficacy, BCG must be given in a maintenance schedule.	1a
Three-year maintenance is more effective than one year to prevent recurrence in patients with high-risk tumours, but not in patients with intermediate-risk tumours.	1a

7.4.4 Combination therapy

7.4.4.1 Intravesical BCG plus chemotherapy versus BCG alone

In one RCT, a combination of MMC and BCG was shown to be more effective in reducing the risk of disease recurrence while increasing toxicity compared to BCG monotherapy (LE: 1b). Using similar BCG schedules in both groups, each BCG instillation in the combination group was preceded a day before by an added MMC instillation [344]. In a RCT using MMC with EMDA, a combination of BCG and MMC with EMDA showed an improved recurrence-free interval and reduced progression rate compared to BCG monotherapy [300, 345] (LE: 2). Two meta-analyses demonstrated improved disease-free survival (DFS), but no benefit in PFS in patients treated with combination treatment comparing to BCG monotherapy [345, 346].

7.4.4.2 Combination treatment using interferon

In a Cochrane meta-analysis of 4 RCTs, a combination of BCG and IFN-2 α did not show a clear difference in recurrence and progression over BCG alone [347]. In one study, weekly MMC followed by monthly BCG alternating with IFN-2 α showed a higher probability of recurrence compared to MMC followed by BCG alone [348]. Additionally, a RCT in a similar population of NMIBC comparing BCG monotherapy with a combination of epirubicin and INF for up to two years showed the latter was significantly inferior to BCG monotherapy in preventing recurrence [349] (LE: 1b).

7.4.4.3 Sequential chemotherapy instillations

Preclinical data suggest that the efficacy of intravesical chemotherapy instillations can be improved by combinations compared to the administration of single agents only [350]. Sequential (immediate) instillations of gemcitabine and docetaxel was initially reported in 2015 in the wake of BCG-shortage but also at times of limited access to mitomycin [351]. Subsequently other sequential chemotherapy combinations such as valrubicin and docetaxel have been suggested [352]. Over time, additional retrospective data have accumulated where sequential gemcitabine and docetaxel instillations were used in patients recurring after induction BCG and BCG-unresponsive disease [353]; in patients with recurrence after BCG-induction but not fulfilling the criteria for BCG-unresponsive disease [354]; and also in BCG-naïve high-risk patients [355]. Thus, in patients with BCG-unresponsive disease when the treatment standard (radical cystectomy) is not feasible due to age and/or comorbidity or when patients are unwilling to accept radical surgery, sequential instillations with gemcitabine and docetaxel is an emerging treatment concept awaiting further prospective scientific evaluation.

7.4.5 Specific aspects of treatment of carcinoma in situ

7.4.5.1 Treatment strategy

The detection of concurrent CIS increases the risk of recurrence and progression of TaT1 tumours [222, 224]. In this case further treatment according to the criteria summarised in Sections 7.4.2, 7.4.3 and 7.9 is mandatory. Carcinoma *in situ* cannot be cured by an endoscopic procedure alone. Histological diagnosis of CIS must be followed by further treatment, either intravesical BCG instillations or RC (LE: 4). Tumour-specific survival rates after immediate RC for CIS are excellent, but a large proportion of patients might be over-treated [232] (LE: 3).

7.4.5.2 Cohort studies on intravesical BCG or chemotherapy

In retrospective evaluations of patients with CIS, a complete response rate of 48% was achieved with intravesical chemotherapy and 72–93% with BCG [232-235, 356] (LE: 2a). Up to 50% of complete responders might eventually show recurrence with a risk of invasion and/or extravesical recurrence [235, 273, 336, 356] (LE: 3).

7.4.5.3 Prospective randomised trials on intravesical BCG or chemotherapy

Unfortunately, there have been few RCTs in patients with CIS only. A meta-analysis of clinical trials comparing intravesical BCG to intravesical chemotherapy in patients with CIS has shown a significantly increased response rate after BCG and a reduction of 59% in the odds of treatment failure with BCG [357] (LE: 1a).

In an EORTC-GUCG meta-analysis of tumour progression, in a subgroup of 403 patients with CIS, BCG reduced the risk of progression by 35% as compared to intravesical chemotherapy or immunotherapy [281] (LE: 1b). The combination of BCG and MMC was not superior to BCG alone [358]. In summary, compared to chemotherapy, BCG treatment of CIS increases the complete response rate, the overall percentage of patients who remain disease free, and reduces the risk of tumour progression (LE: 1b).

7.4.5.4 Treatment of CIS in the prostatic urethra and upper urinary tract

Patients with CIS are at high risk of extravesical involvement in the UUT and in the prostatic urethra. Solsona *et al.*, found that 63% of 138 patients with CIS developed extravesical involvement initially or during follow-up [359]. Patients with extravesical involvement had worse survival than those with bladder CIS alone [359] (LE: 3). In the prostate, CIS might be present only in the epithelial lining of the prostatic urethra or in the prostatic ducts [360]. These situations should be distinguished from tumour invasion into the prostatic stroma (stage T4a in bladder tumours) and for which immediate radical cystoprostatectomy is mandatory. Patients with CIS in the epithelial lining of the prostatic urethra can be treated by intravesical instillation of BCG. Transurethral resection of the prostate can improve contact of BCG with the prostatic urethra [146, 361] (LE: 3). However, potential spread of CIS has to be considered; no suprapubic trocar-placed catheter should be used.

In patients with prostatic duct involvement there are promising results of BCG, but only from small series. The data are insufficient to provide clear treatment recommendations and radical surgery should be considered [361, 362] (LE: 3).

7.4.5.5 Summary of evidence - treatment of carcinoma in situ

Summary of evidence	LE
Carcinoma <i>in situ</i> cannot be cured by an endoscopic procedure alone.	4
Compared to intravesical chemotherapy, intravesical BCG maintenance instillations increase the complete response rate, the overall percentage of patients who remain disease free, and reduce the risk of tumour progression.	1b

7.5 Intravesical chemoablation and neoadjuvant treatment

Older marker lesion studies have shown that chemoablation with a single intravesical chemotherapy instillation can achieve a complete response in a proportion of patients [363]. **In addition, hypothesis-generating findings from an older RCT comparing immediate pre-operative device-assisted (EMDA) MMC with post-operative SI with MMC and TURB only, showed improved long-term RFS among patients treated prior to TURB [364], and thus even suggest a long-term effect after neoadjuvant instillations.** While this has not been reproduced by other groups, additional neoadjuvant clinical trials were recently published. In recurrent low-risk [365] and recurrent Ta tumours [366], 4 and 6 intravesical MMC instillations achieved complete response in 37% and 57% of the patients, respectively. The former study prematurely stopped recruitment as the anticipated 45% complete response after chemoablation was not achieved. Compared to TURB, less dysuria and incontinence occurred in the intervention arm of the trial. Before routine clinical application, additional high-level evidence with RFS as an outcome measure is required.

7.6 Radical cystectomy for non-muscle-invasive bladder cancer

There are several reasons to consider immediate RC for selected patients with NMIBC:

- The staging accuracy for T1 tumours by TURB is low with 27–51% of patients being upstaged to muscle-invasive tumour at RC [182, 367-371] (LE: 3).
- Some patients with NMIBC experience disease progression to muscle-invasive disease (Table 6.2).
- Patients who experience disease progression to muscle-invasive stage have a worse prognosis than those who present with ‘primary’ muscle-invasive disease [372, 373].

7.9 Treatment of failure of intravesical therapy

7.9.1 Recurrence during or after intravesical chemotherapy

Patients with NMIBC recurrence during or after a chemotherapy regimen can benefit from BCG instillations. Prior intravesical chemotherapy has no impact on the effect of BCG instillations [282] (LE: 1a).

7.9.2 Treatment failure after intravesical BCG immunotherapy

Several categories of BCG failures, broadly defined as any HG disease occurring during or after BCG therapy, have been proposed (see Table 7.2). Non-muscle-invasive BC may not respond at all (BCG refractory) or may relapse after initial response (BCG relapsing). Some evidence suggests that patients with BCG relapse have better outcomes than BCG refractory patients [383].

To be able to specify the subgroup of patients where additional BCG is unlikely to provide benefit, the category of BCG-unresponsive tumour was defined. Further BCG instillations in these patients are associated with an increased risk of progression [236, 384]. The category of BCG-unresponsive tumours comprises BCG-refractory and some of BCG-relapsing tumours (see Table 7.2) [385]. The definition was developed in consultation with the U.S. Food and Drug Administration (FDA), in particular to promote single-arm trials to provide primary evidence of effectiveness in this setting [386]. Non-HG recurrence after BCG is not considered as BCG failure.

Table 7.2: Categories of high-grade recurrence during or after BCG

Whenever a MIBC is detected during follow-up.
BCG-refractory tumour
1. If T1 HG/G3 tumour is present at 3 months [236, 384, 387] (LE: 3).
2. If Ta HG/G3 tumour is present after 3 months and/or at 6 months, after either re-induction or first course of maintenance [360] (LE: 4).
3. If CIS (without concomitant papillary tumour) is present at 3 months and persists at 6 months after either re-induction or first course of maintenance. If patients with CIS present at 3 months, an additional BCG course can achieve a complete response in > 50% of cases [67, 356, 360] (LE: 1b).
4. If HG tumour appears during BCG maintenance therapy*.
BCG-relapsing tumour
Recurrence of HG/G3) tumour after completion of BCG maintenance, despite an initial response [388] (LE: 3).
BCG-unresponsive tumour
BCG-unresponsive tumours include all BCG refractory tumours and those who develop T1/Ta HG recurrence within 6 months of completion of adequate BCG exposure** or develop CIS within 12 months of completion of adequate BCG exposure [385] (LE: 4).
BCG intolerance
Severe side effects that prevent further BCG instillation before completing treatment [330].

* Patients with LG recurrence during or after BCG treatment are not considered to be a BCG failure.

** Adequate BCG is defined as the completion of at least 5 of 6 doses of an initial induction course plus at least 2 out of 6 doses of a second induction course or 2 out of 3 doses of maintenance therapy.

7.9.3 Treatment of BCG-unresponsive tumours, late BCG-relapsing tumours, LG recurrences after BCG treatment and patients with BCG intolerance

Patients with BCG-unresponsive disease are unlikely to respond to further BCG therapy; RC is therefore the standard and preferred option. Currently, several bladder preservation strategies are being investigated such as cytotoxic intravesical therapies [389-392], device assisted instillations [393-395], intravesical immunotherapy [396, 397], systemic immunotherapy [398] or gene therapy [399-401].

A phase III RCT including predominantly high-risk NMIBC patients failing at least a previous induction course of BCG, MMC combined with microwave-induced hyperthermia provided 35% overall DFS at 2 years as compared to 41% in the control arm (treated with either BCG, MMC or MMC and electromotive drug administration at the discretion of the investigator). In the pre-planned sub-analysis, MMC and microwave-induced thermotherapy showed lower response rates in CIS recurrences but higher DFS in non-CIS papillary tumours (53% vs. 24%) [395].

295. Zhao, H., *et al.* Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. *Front Surg*, 2021. 8: 775527.
<https://pubmed.ncbi.nlm.nih.gov/34888347/>
296. Arends, T.J., *et al.* Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. *J Urol*, 2014. 192: 708.
<https://pubmed.ncbi.nlm.nih.gov/24704017/>
297. Arends, T.J., *et al.* Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. *Eur Urol*, 2016. 69: 1046.
<https://pubmed.ncbi.nlm.nih.gov/26803476/>
298. Tan, W.S., *et al.* Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. *Eur Urol*, 2022.
<https://pubmed.ncbi.nlm.nih.gov/35999119/>
299. Guerrero-Ramos, F., *et al.* Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. *World J Urol*, 2022. 40: 999.
<https://pubmed.ncbi.nlm.nih.gov/35037963/>
300. Di Stasi, S.M., *et al.* Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol*, 2006. 7: 43.
<https://pubmed.ncbi.nlm.nih.gov/16389183/>
301. Shelley, M.D., *et al.* A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. *BJU Int*, 2001. 88: 209.
<https://pubmed.ncbi.nlm.nih.gov/11488731/>
302. Han, R.F., *et al.* Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. *Urology*, 2006. 67: 1216.
<https://pubmed.ncbi.nlm.nih.gov/16765182/>
303. Shelley, M.D., *et al.* Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. *BJU Int*, 2004. 93: 485.
<https://pubmed.ncbi.nlm.nih.gov/15008714/>
304. Bohle, A., *et al.* Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. *J Urol*, 2003. 169: 90.
<https://pubmed.ncbi.nlm.nih.gov/12478111/>
305. Duchek, M., *et al.* Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. *Eur Urol*, 2010. 57: 25.
<https://pubmed.ncbi.nlm.nih.gov/19819617/>
306. Jarvinen, R., *et al.* Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma *in situ*: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. *Eur Urol*, 2009. 56: 260.
<https://pubmed.ncbi.nlm.nih.gov/19395154/>
307. Schmidt, S., *et al.* Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. *Cochrane Database Syst Rev*, 2020. 1: CD011935.
<https://pubmed.ncbi.nlm.nih.gov/31912907/>
308. Huncharek, M., *et al.* The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. *Am J Clin Oncol*, 2004. 27: 522.
<https://pubmed.ncbi.nlm.nih.gov/15596924/>
309. Oddens, J.R., *et al.* The effect of age on the efficacy of maintenance bacillus calmette-guerin relative to maintenance epirubicin in patients with stage ta t1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. *Eur Urol*, 2014. 66: 694.
<https://pubmed.ncbi.nlm.nih.gov/24948466/>
310. Miyake, M., *et al.* Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. *BJU Int*, 2018. 121: 764.
<https://pubmed.ncbi.nlm.nih.gov/29281857/>

360. Sylvester, R.J., *et al.* High-grade Ta urothelial carcinoma and carcinoma *in situ* of the bladder. *Urology*, 2005. 66: 90.
<https://pubmed.ncbi.nlm.nih.gov/16399418/>
361. Palou, J., *et al.* Urothelial carcinoma of the prostate. *Urology*, 2007. 69: 50.
<https://pubmed.ncbi.nlm.nih.gov/17280908/>
362. Palou Redorta, J., *et al.* Intravesical instillations with bacillus calmette-guerin for the treatment of carcinoma *in situ* involving prostatic ducts. *Eur Urol*, 2006. 49: 834.
<https://pubmed.ncbi.nlm.nih.gov/16426729/>
363. Popert, R.J., *et al.* Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. *Br J Urol*, 1994. 74: 195.
<https://pubmed.ncbi.nlm.nih.gov/7921938/>
364. Di Stasi, S.M., *et al.* Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. *Lancet Oncol*, 2011. 12: 871.
<https://pubmed.ncbi.nlm.nih.gov/21831711/>
365. Mostafid, A.H., *et al.* CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. *BJU Int*, 2020. 125: 817.
<https://pubmed.ncbi.nlm.nih.gov/32124514/>
366. Lindgren, M.S., *et al.* The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial. *Eur Urol*, 2020. 78: 856.
<https://pubmed.ncbi.nlm.nih.gov/32736928/>
367. Fritsche, H.M., *et al.* Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol*, 2010. 57: 300.
<https://pubmed.ncbi.nlm.nih.gov/19766384/>
368. Turker, P., *et al.* Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. *BJU Int*, 2012. 110: 804.
<https://pubmed.ncbi.nlm.nih.gov/22321341/>
369. May, M., *et al.* Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. *Scand J Urol Nephrol*, 2011. 45: 251.
<https://pubmed.ncbi.nlm.nih.gov/21388337/>
370. Svatek, R.S., *et al.* Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int*, 2011. 107: 898.
<https://pubmed.ncbi.nlm.nih.gov/21244604/>
371. Shariat, S.F., *et al.* Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol*, 2007. 51: 137.
<https://pubmed.ncbi.nlm.nih.gov/16793197/>
372. Moschini, M., *et al.* Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. *BJU Int*, 2016. 117: 604.
<https://pubmed.ncbi.nlm.nih.gov/25851271/>
373. Schrier, B.P., *et al.* Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. *Eur Urol*, 2004. 45: 292.
<https://pubmed.ncbi.nlm.nih.gov/15036673/>
374. Kamat, A.M., *et al.* The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. *J Urol*, 2006. 175: 881.
<https://pubmed.ncbi.nlm.nih.gov/16469571/>
375. Raj, G.V., *et al.* Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. *J Urol*, 2007. 177: 1283.
<https://pubmed.ncbi.nlm.nih.gov/17382713/>
376. Stein, J.P., *et al.* Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol*, 2001. 19: 666.
<https://pubmed.ncbi.nlm.nih.gov/11157016/>
377. Hautmann, R.E., *et al.* Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. *Eur Urol*, 2012. 61: 1039.
<https://pubmed.ncbi.nlm.nih.gov/22381169/>
378. Shariat, S.F., *et al.* Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol*, 2006. 176: 2414.
<https://pubmed.ncbi.nlm.nih.gov/17085118/>

379. Kurpad, R., *et al.* A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? *Urol Oncol*, 2011. 29: 378.
<https://pubmed.ncbi.nlm.nih.gov/19576797/>
380. Wayment, R.O., *et al.* Second opinion pathology in tertiary care of patients with urologic malignancies. *Urol Oncol*, 2011. 29: 194.
<https://pubmed.ncbi.nlm.nih.gov/19523859/>
381. Traboulsi, S.L., *et al.* Pathology review impacts clinical management of patients with T1-T2 bladder cancer. *Can Urol Assoc J*, 2017. 11: 188.
<https://pubmed.ncbi.nlm.nih.gov/28652877/>
382. Luchey, A.M., *et al.* Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. *Urology*, 2016. 93: 130.
<https://pubmed.ncbi.nlm.nih.gov/27041469/>
383. Herr, H.W., *et al.* BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. *Urol Oncol*, 2015. 33: 108.e1.
<https://pubmed.ncbi.nlm.nih.gov/25813144/>
384. Lerner, S.P., *et al.* Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. *Urol Oncol*, 2009. 27: 155.
<https://pubmed.ncbi.nlm.nih.gov/18367117/>
385. Kamat, A.M., *et al.* Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. *J Clin Oncol*, 2016. 34: 1935.
<https://pubmed.ncbi.nlm.nih.gov/26811532/>
386. U.S. Food and Drug Administration (FDA). BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment. Guidance for Industry. Center for Drug Evaluation and Research (CDER). 2018. [access date December 2022].
<https://www.fda.gov/media/101468/download>
387. Herr, H.W., *et al.* Defining bacillus Calmette-Guerin refractory superficial bladder tumors. *J Urol*, 2003. 169: 1706.
<https://pubmed.ncbi.nlm.nih.gov/12686813/>
388. van den Bosch, S., *et al.* Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. *Eur Urol*, 2011. 60: 493.
<https://pubmed.ncbi.nlm.nih.gov/21664041/>
389. Cockerill, P.A., *et al.* Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. *BJU Int*, 2016. 117: 456.
<https://pubmed.ncbi.nlm.nih.gov/25682834/>
390. Barlow, L., *et al.* A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. *BJU Int*, 2009. 104: 1098.
<https://pubmed.ncbi.nlm.nih.gov/19389012/>
391. Steinberg, G., *et al.* Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma *in situ* of the bladder. The Valrubicin Study Group. *J Urol*, 2000. 163: 761.
<https://pubmed.ncbi.nlm.nih.gov/10687972/>
392. Jones, G., *et al.* Intravesical gemcitabine for non-muscle invasive bladder cancer. *Cochrane Database Syst Rev*, 2012. 1: CD009294.
<https://pubmed.ncbi.nlm.nih.gov/22259002/>
393. Nativ, O., *et al.* Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. *J Urol*, 2009. 182: 1313.
<https://pubmed.ncbi.nlm.nih.gov/19683278/>
394. Racioppi, M., *et al.* ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes. *BMC Cancer*, 2018. 18: 1224.
<https://pubmed.ncbi.nlm.nih.gov/30522445/>
395. Tan, W.S., *et al.* Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. *Eur Urol*, 2019. 75: 63.
<https://pubmed.ncbi.nlm.nih.gov/30274699/>